ClinicalTrials.gov
public full text
Public Domain
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
RATIONALE: Baclofen-amitriptyline-ketamine (BAK) gel may lessen peripheral neuropathy caused by chemotherapy. It is not yet known whether BAK gel is more effective than a placebo in treating peripheral neuropathy caused by chemotherapy . PURPOSE: This randomized phase III trial is studying BAK gel to see how well it works compared with a placebo in treating peripheral neuropathy caused by chemotherapy in patients with cancer.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Lamotrigine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer#871079
- Chemotherapy-induced Peripheral Neuropathy (CIPN) on Motor and Sensory Function#1072198
- Electrical Stimulation and Chemotherapy Induced Peripheral Neuropathy#1126407
- Light Therapy for Chemotherapy Induced Peripheral Neuropathy in Childhood Cancer Survivors#836456
- Assessing Functional Impairments in Patients With Chemotherapy-Induced Peripheral Neuropathy#878275
Record · ID 881792
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive